The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic

Cell, Journal Year: 2021, Volume and Issue: 185(3), P. 447 - 456.e11

Published: Dec. 24, 2021

Language: Английский

---

SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo

Nature, Journal Year: 2022, Volume and Issue: 603(7902), P. 715 - 720

Published: Feb. 1, 2022

Language: Английский

---

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway

Nature Microbiology, Journal Year: 2022, Volume and Issue: 7(8), P. 1161 - 1179

Published: July 7, 2022

Vaccines based on the spike protein of SARS-CoV-2 are a cornerstone public health response to COVID-19. The emergence hypermutated, increasingly transmissible variants concern (VOCs) threaten this strategy. Omicron (B.1.1.529), fifth VOC be described, harbours multiple amino acid mutations in spike, half which lie within receptor-binding domain. Here we demonstrate substantial evasion neutralization by BA.1 and BA.2 vitro using sera from individuals vaccinated with ChAdOx1, BNT162b2 mRNA-1273. These data were mirrored reduction real-world vaccine effectiveness that was partially restored booster vaccination. did not induce cell syncytia favoured TMPRSS2-independent endosomal entry pathway, these phenotypes mapping distinct regions protein. Impaired fusion determined domain, while mapped S2 Such marked changes antigenicity replicative biology may underlie rapid global spread altered pathogenicity variant.

Language: Английский

---

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

Nature, Journal Year: 2021, Volume and Issue: 602(7898), P. 682 - 688

Published: Dec. 31, 2021

Language: Английский

---

The emergence and epidemic characteristics of the highly mutated SARS‐CoV‐2 Omicron variant

Journal of Medical Virology, Journal Year: 2022, Volume and Issue: 94(6), P. 2376 - 2383

Published: Feb. 4, 2022

Recently, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529) was first identified in Botswana November 2021. It reported to World Health Organization (WHO) on 24. On 26, 2021, according advice of scientists who are part WHO's Technical Advisory Group SARS-CoV-2 Virus Evolution (TAG-VE), WHO defined strain as a concern (VOC) and named it Omicron. Compared other four VOCs (Alpha, Beta, Gamma, Delta), most highly mutated strain, with 50 mutations accumulated throughout genome. The contains at least 32 spike protein, which twice many Delta variant. Studies have shown that carrying can increase infectivity immune escape compared early wild-type VOCs. is becoming dominant countries worldwide brings new challenges preventing controlling disease 2019 (COVID-19). current review article aims analyze summarize information data about biological characteristics amino acid mutations, epidemic characteristics, escape, vaccine reactivity variant, hoping provide scientific reference for monitoring, prevention, development strategies

Language: Английский

---

Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic

Environmental Research, Journal Year: 2022, Volume and Issue: 209, P. 112816 - 112816

Published: Jan. 29, 2022

Language: Английский

---

Structural biology of SARS-CoV-2: open the door for novel therapies

Signal Transduction and Targeted Therapy, Journal Year: 2022, Volume and Issue: 7(1)

Published: Jan. 27, 2022

Abstract Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the causative agent of pandemic disease COVID-19, which so far without efficacious treatment. The discovery therapy reagents for treating COVID-19 are urgently needed, and structures potential drug-target proteins in viral life cycle particularly important. SARS-CoV-2, a member Orthocoronavirinae subfamily containing largest RNA genome, encodes 29 including nonstructural, structural accessory involved adsorption, entry uncoating, nucleic acid replication transcription, assembly release, etc. These individually act as partner machinery or forming complexes with host cellular factors to participate essential physiological activities. This review summarizes representative typically agents that target SARS-CoV-2 some critical pathogenesis, providing insights into mechanisms underlying infection, prevention Indeed, these studies open door COVID therapies, leading ways prevent treat especially, treatment caused by variants imperative.

Language: Английский

---

SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance

Signal Transduction and Targeted Therapy, Journal Year: 2021, Volume and Issue: 6(1)

Published: Dec. 17, 2021

---

Investigation of a SARS-CoV-2 B.1.1.529 (Omicron) Variant Cluster — Nebraska, November–December 2021

MMWR Morbidity and Mortality Weekly Report, Journal Year: 2021, Volume and Issue: 70(5152), P. 1782 - 1784

Published: Dec. 28, 2021

The B.1.1.529 (Omicron) variant of SARS-CoV-2 (the virus that causes COVID-19) was first detected in specimens collected on November 11, 2021, Botswana and 14 South Africa;* the confirmed case Omicron United States identified California December 1, 2021 (1). On 29, Nebraska Department Health Human Services notified six probable cases† COVID-19 one household, including a man aged 48 years index patient) who had recently returned from Nigeria. Given patient's travel history, infection suspected. Specimens all persons household tested positive for by reverse transcription-polymerase chain reaction (RT-PCR) testing following day genomic sequencing Public Laboratory an identical genotype each specimen (Figure). Phylogenetic analysis conducted to determine if this cluster represented independent introduction into States, detailed epidemiologic investigation conducted. This activity reviewed CDC consistent with applicable federal law policy.§.

Language: Английский

---

Transmission of SARS-CoV-2 delta variant (AY.127) from pet hamsters to humans, leading to onward human-to-human transmission: a case study

The Lancet, Journal Year: 2022, Volume and Issue: 399(10329), P. 1070 - 1078

Published: March 1, 2022

Language: Английский

---